Li Z,Li Y,Chen Y,et al. Trends of pulmonary fungal infections from 2013 to 2019:an AI-based real-world observational study in Guangzhou, China[J].Emerg Microbes Infect,2021,10(1):450-460.
[2]
Seagle E E,Williams S L,Chiller T M.Recent trends in the epidemiology of fungal infections[J].Infect Dis Clin N Am,2021,35(2):237-260.
Firacative C.Invasive fungal disease in humans:are we aware of the real impact?[J].Mem Inst Oswaldo Cruz,2020,115:e200430.
[6]
Cornely O A,Alastruey I A,Arenz D,et al.Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium[J]. Lancet Infect Dis,2019,19(12):e 405-e421.
[7]
Pagano L,Cattaneo C,Quattrone M,et al.Isavuconazole-animal data and clinical data[J].J Fungi(Basel),2020, 6(4):209.
[8]
Dagher H,Hachem R,Chaftari A,et al.Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant[J].J Fungi(Basel),2022,8(1):74.
[9]
Hassouna H,Athans V,Brizendine K D.Real-world use-Isavuconazole at a large academic medical center[J]. Mycoses,2019,62(6):534-541.
Jenks J D,Metha S R,Hoenigl M.Broad spectrum triazoles for invasive mould infections in adults: which drug and when?[J].Med Mycol,2019,57(Suppl 2): S168-S178.
[12]
Ananda-Rajah M R,Kontoyiannis D. Isavuconazole:a new extended spectrum triazole for invasive mold dis- eases[J].Future Microbiol,2015,10(5):693-708.
[13]
Ellsworth M,Ostrosky-Zeichner L.Isavuconazole:mechanism of action,clinical efficacy and resistance[J]. J Fungi (Basel),2020,6(4):324.
2024, Vol. 35 
